US 12,233,070 B2
Methods for treating benzodiazepine misuse/use disorder
James K. Rowlett, Ridgeland, MS (US)
Assigned to UNIVERSITY OF MISSISSIPPI MEDICAL CENTER, Jackson, MS (US)
Filed by University of Mississippi Medical Center, Jackson, MS (US)
Filed on Jun. 29, 2021, as Appl. No. 17/361,754.
Claims priority of provisional application 63/046,615, filed on Jun. 30, 2020.
Prior Publication US 2021/0401849 A1, Dec. 30, 2021
Int. Cl. A61P 25/30 (2006.01); A61K 31/501 (2006.01); A61K 31/5025 (2006.01); A61K 31/53 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 31/501 (2013.01); A61K 31/5025 (2013.01); A61P 25/30 (2018.01)] 16 Claims
 
1. A method of treating benzodiazepine misuse and/or use disorder, the method comprising:
identifying a subject as having benzodiazepine misuse and/or use disorder; and
administering to the subject an effective amount of a compound providing partial modulatory effects for α2 and α3 GABAA receptor subtypes, the compound comprising the structure:

OG Complex Work Unit Chemistry
wherein the compound is administered at a dose of greater than or equal to about 0.03 mg/kg
wherein administration of the compound suppresses benzodiazepine self-administration, wherein the suppression is insurmountable and is not negated by increased benzodiazepine dosing, and
wherein administration of the compound does not precipitate benzodiazepine withdrawal in the subject.